These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 11708768)

  • 1. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
    Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a chimeric synthetic peptide from the core p19 protein and the envelope gp46 glycoprotein in the immunodiagnosis of HTLV-II virus infection.
    Hernández Marin M; Márquez Bocalandro Y; Vallejo RV; Rodríguez Tanty C; Higginson Clark D; Pozo Peña L; Silva León C
    Prep Biochem Biotechnol; 2003 Feb; 33(1):29-38. PubMed ID: 12693813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
    Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
    Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic mixture of synthetic peptides for the immunodiagnosis of HTLV I/II infection.
    Bocalandro YM; Marin MH; Vallejo RA; Peña LP; León CS; Martínez GR; Tanty CR; Clarke DH; Velázquez SB
    J Immunoassay Immunochem; 2004; 25(3):205-14. PubMed ID: 15461383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric synthetic peptides from the nucleocapsid p24 protein of human immunodeficiency virus type-1.
    Hernández M; Rodríguez I; Pozo L; Rivero J
    Biochem Biophys Res Commun; 2001 Mar; 282(1):1-3. PubMed ID: 11263961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
    Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II).
    Tanaka Y; Tanaka R; Hoshino H
    Int J Cancer; 1994 Dec; 59(5):655-60. PubMed ID: 7525496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic activity of three chimeric synthetic peptides of the transmembrane (gp41) and the envelope (gp120) glycoproteins of HIV-1 virus.
    Marin MH; Peña LP; Tanty CR; Higginson Clarke D; Arenas MA; Noguerol KR; León CS
    Prep Biochem Biotechnol; 2004 Aug; 34(3):227-37. PubMed ID: 15461139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric synthetic peptide as antigen for immunodiagnosis of HIV-1 infection.
    Hernández M; Pozo L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 May; 272(1):259-62. PubMed ID: 10872836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunoreactivity of synthetic peptides, corresponding to B-cellular epitopes of human type I T-lymphotrophic virus structural proteins].
    Rasuli AM; Klepikov NN; Andreev SM; Sidorova MV; Vafina MG; Seniuta NB; Pavlish OA; Syrtsev AV; Gurtsevich VE
    Mol Biol (Mosk); 1993; 27(4):880-7. PubMed ID: 8361494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of immunodominant epitopes in envelope glycoprotein of human T lymphotropic virus type II.
    Lal RB; Rudolph DL; Kaplan JE; Hjelle B; Levine PH; Coligan JE; Viscidi RP
    Virology; 1992 Jan; 186(1):274-9. PubMed ID: 1727602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.